Jazz Pharmaceuticals plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JAZZ research report →
Range $220 – $337
Price Chart
About the company
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
- CEO
- Renee D. Gala
- IPO
- 2007
- Employees
- 2,890
- HQ
- Dublin, DU, IE
AI snapshot
Six angles, distilled from the data.
The stock remains in a constructive multi-month uptrend, trading above both the 50-day and 200-day moving averages. It is still below the 52-week high of 266.38, so the setup is strong but not stretched into a fresh breakout regime.
Street sentiment stays constructive, with a Buy consensus and a 295.73 average target versus the current share price. Recent target moves have been mixed but mostly supportive, including JPMorgan at $300, Morgan Stanley at $314, and Bernstein trimming to $220 while keeping a neutral stance.
Earnings momentum is uneven but workable: Jazz has beaten in 5 of the last 8 quarters, including a 6.8% EPS beat in the latest report. Next-year EPS estimates still point sharply higher to 26.7428, so shareholders should watch whether the company can keep translating revenue growth into cleaner earnings execution.
Recent insider activity leans negative on discretionary trades, led by multiple open-market sales from the CEO and a director, plus selling from the Chief Accounting Officer. The large director filings also include automatic exempt transactions, but the repeated S-sale pattern suggests insiders have been taking chips off the table rather than adding.
Profitability is solid, with a 91.1% gross margin and 27.39% operating margin, while revenue grew 10.4% year over year. Free cash flow was $1.566 billion in fiscal 2025, but the balance sheet still carries net debt of about $2.98 billion, so cash generation remains the key offset.
Jazz screens as a profitable specialty biotech with stronger margins than many peers, supported by high gross margins and double-digit revenue growth. At 8.82 times earnings, the valuation looks modest relative to the growth profile and well below the consensus target range.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.78B
- P/E
- 64.32
- Fwd P/E
- 15.42
- PEG
- 0.04
- P/S
- 3.13
- P/B
- 3.55
- EV/EBITDA
- 15.72
- Div Yield
- 0.00%
- Gross Margin
- 88.17%
- Op Margin
- 20.30%
- Net Margin
- 4.37%
- ROE
- 4.62%
- ROIC
- 7.24%
Latest fiscal year · YoY change
- Revenue
- $4.27B+4.9%
- Gross Profit
- $3.76B+3.9%
- Op Income
- $224.42M
- Net Income
- $-356,148,000-163.6%
- EPS
- $-5.84-164.5%
- OCF Growth
- -2.9%
- FCF Growth
- -15.0%
- 52W High
- $266.38
- 52W Low
- $156.95
- 50D MA
- $229.05
- 200D MA
- $221.53
- Beta
- 0.32
- RSI (14)
- 54
- Avg Volume
- 897.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Jazz delivered record third-quarter revenue and raised full-year guidance, led by strong Xywav performance and an early but promising Ziihera launch.· November 2, 2026
- Record Q3 revenue was $1.24 billion, up 10% year over year, with oncology revenue up 35% and Xywav up 12%.
- Management raised 2026 revenue guidance to $4.775 billion-$4.85 billion and lifted gross margin guidance to 90.5%-91.5%.
- Ziihera’s first-line GEA launch started strongly, with more than 80% of new ordering accounts coming from the community setting in September.
- Xywav remained durable despite orexin competition and high-sodium generics, with 17,550 active patients at quarter-end.
- Modeyso continues to ramp, but management expects a more measured pace near term ahead of ACTION data in the first half of 2027.
Jazz reported third-quarter 2026 revenue of $1.24 billion, up 10% year over year. Xywav net product sales increased 12% to $483 million; Epidiolex sales were $295 million; Ziihera generated $21 million; Modeyso has generated approximately $200 million since launch; and Zepzelca sales increased 32% to $104 million. Non-GAAP adjusted gross margin declined by 110 basis points year over year, while non-GAAP adjusted SG&A increased $19 million or 6% excluding litigation charges and non-GAAP adjusted R&D increased 11%. Non-GAAP EPS was positive at $7.15 excluding the $754 million Actio acquired IPR&D charge, while reported non-GAAP EPS was a loss of $3.88. For 2026, Jazz raised and narrowed total revenue guidance to $4.775 billion-$4.85 billion, raised rare sleep revenue guidance to $2.125 billion-$2.175 billion, increased gross margin guidance to 90.5%-91.5%, left SG&A and R&D guidance unchanged, updated the non-GAAP tax rate to 19.5%-21.5%, and left share count guidance at 69 million-70 million shares.
Renee Galá said the quarter showed progress toward a more innovative and diversified Jazz, highlighting record revenue, the Ziihera approval and launch, and the Actio acquisition as key steps in building future growth. She emphasized disciplined capital allocation and said the company is positioned to keep investing in current products, the pipeline, and business development. Her tone was confident and forward-looking, with several near-term milestones called out, including initial ABS-1230 data this quarter and ACTION and EmpowHER readouts in 2027-2028.
Phil Johnson emphasized that the revenue beat came from strong execution across multiple products, especially Xywav and the oncology portfolio, and noted that the prior-year quarter had 14 shipping weeks versus 13 this year, creating a 9-point headwind to U.S. oncology growth. He said gross margin fell 110 basis points year over year mainly due to royalties on higher Modeyso and Zepzelca sales and manufacturing tech transfers. He also highlighted $1.3 billion of operating cash flow in the first nine months, $1.25 billion of convertible notes issued, a reduced interest rate and extended term loan maturity, $820 million spent on Actio, and quarter-end cash and investments of $2.9 billion.
Analysts focused on what drove the raised guidance, and management said more than half of the increase came from the rare sleep franchise, with Xywav outperforming and high-sodium generic erosion coming in below expectations. Questions on Ziihera centered on community uptake, ordering accounts, and whether the product was contributing meaningfully to guidance; management said the launch is in line with expectations but too early to materially move 2026 revenue because it launched late in the year. Analysts also pressed on Xywav’s resilience versus orexin and generic competition, Modeyso’s near-term pace, Zepzelca’s outlook versus IMDELLTRA, and whether Zenidatamab could gain NCCN category 1 status; management repeatedly pointed to strong community adoption, smooth reimbursement, and the belief that current data support broader access.
The call showed multiple growth engines working at once: Xywav remained highly durable, Epidiolex was steady, and Ziihera had an encouraging first month with strong community adoption and no major reimbursement friction. Management also sounded confident that Ziihera’s data can support broader uptake and potentially a stronger NCCN position, while Modeyso and ABS-1230 add additional optionality to the pipeline. The raised revenue and gross margin guidance suggest the commercial base is generating enough cash to fund growth and external development.
Management acknowledged that some products face future pressure: Zepzelca is likely to see a competitive headwind in 2027 if IMDELLTRA is approved in the maintenance setting, and Modeyso is expected to grow at a more measured pace until ACTION data arrives. Xywav could face slower initiation timing in narcolepsy as orexin therapies enter the market, even though management does not expect major share loss. Ziihera is still very early, and the company is not yet seeing enough contribution for it to materially change 2026 guidance.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.0%
- Shares Outstanding
- 64.19M
- Float Shares
- 62.25M
of shares held by institutions
666 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for JAZZ, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 19, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Mar 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 14, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jan 31, 23 | Filing → |
| Thomas SuozziHouse · NY03 | Sell | Sep 26, 22 | Filing → |
| Thomas SuozziHouse · NY03 | Buy | Oct 19, 21 | Filing → |
| Bill FloresHouse · TX17 | Buy | Jul 15, 19 | Filing → |
| Carlos CurbeloHouse · FL26 | Buy | Aug 28, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.45M | ▲ 485.86K |
| Vanguard Group Inc | 5.92M | ▲ 10.20K |
| Fmr LLC | 5.54M | ▲ 934.49K |
| Vanguard Portfolio Management LLC | 3.07M | ▲ 35.55K |
| Vanguard Capital Management LLC | 2.81M | ▲ 75.53K |
| Capital World Investors | 2.39M | ▼ 304.22K |
| Lsv Asset Management | 2.14M | ▼ 139.21K |
| State Street Corp | 2.07M | ▲ 68.17K |
| Franklin Templeton Inc | 1.94M | ▼ 96.28K |
| Geode Capital Management, LLC | 1.53M | ▲ 49.53K |
| Aqr Capital Management LLC | 1.52M | ▲ 184.11K |
| Dimensional Fund Advisors LP | 1.45M | ▼ 260.33K |
Held by 700 ETFs
Biggest fund positions in JAZZ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | COZADD BRUCE C | other | 85,766 |
| Nov 6, 26 | COZADD BRUCE C | sell | 27,714 |
| Nov 6, 26 | COZADD BRUCE C | sell | 10,688 |
| Nov 6, 26 | COZADD BRUCE C | sell | 24,483 |
| Nov 6, 26 | COZADD BRUCE C | sell | 5,923 |
| Nov 6, 26 | COZADD BRUCE C | other | 734 |
| Nov 6, 26 | COZADD BRUCE C | other | 734 |
| Nov 6, 26 | COZADD BRUCE C | other | 85,766 |
| Nov 4, 26 | Carr Patricia | other | 1,250 |
| Nov 4, 26 | Carr Patricia | sell | 1,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JAZZ coverage
Recent articles, reports, and earnings notes.

Jazz Pharmaceuticals (JAZZ): Oncology Growth Meets Cash Flow
Jazz Pharmaceuticals posted record third-quarter revenue, with oncology and Xywav driving growth while the stock still trades at a modest forward multiple. The thesis is balanced by heavy debt, product concentration, and looming competition.

Jazz Pharmaceuticals plc (JAZZ) falls 12% after hours
Jazz Pharmaceuticals plc (JAZZ) falls sharply after hours as a broad market risk-off move hits shares, even though the company recently beat Q3 EPS estimates and raised revenue guidance. Investors are weighing valuation, higher costs, and whether the drop holds into regular trading.

Brains Bioceutical Corp.'s De-SPAC: What Investors Need to Know
Brains Bioceutical Corp. is a cannabinoid life sciences and pharmaceutical API company going public through a merger with Armada Acquisition Corp. III (AACI), with closing expected in Q2 2027. The setup offers a differentiated pharma-style cannabinoid story, but shareholders should watch redemption risk, dilution, and the lack of a disclosed PIPE.
Want a deeper read on JAZZ?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Allspring Global Investments Holdings LLC Acquires 42,827 Shares of Jazz Pharmaceuticals PLC $JAZZ
defenseworld.net · Nov 15
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
zacks.com · Nov 9
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Boston Trust Walden Corp
defenseworld.net · Nov 5
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 3
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
zacks.com · Nov 3
4 Biotech Stocks Seeing Unusual Options Volume Today
schaeffersresearch.com · Nov 3
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice